Skip to main content
Erschienen in: Rheumatology International 3/2010

01.01.2010 | Original Article

Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule

verfasst von: Miho Suzuki, Misato Hashizume, Hiroto Yoshida, Masahiko Mihara

Erschienen in: Rheumatology International | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

We studied the influence of IL-6 on chemokine production from peripheral blood mononuclear cells (PBMC), fibroblastic synovial cells and human umbilical vessel endothelial cells (HUVEC). Moreover, we examined the effect of IL-6 on the adhesion of U937 cells to HUVEC. For chemokine production, PBMC, fibroblastic synovial cells and HUVEC were cultured with IL-6 or IL-6 + soluble IL-6R (sIL-6R) for 24 h and then the production of MCP-1 and IL-8 were measured in supernatants. IL-6 and IL-6 + sIL-6R induced production of both MCP-1 and IL-8 in PBMC and synovial cells, respectively. In HUVEC, IL-6 + sIL-6R induced MCP-1 production, but inhibited IL-8 production. For adhesion molecule expression, the production of soluble form of adhesion molecules in HUVEC culture supernatant were measured by ELISA and the expression of adhesion molecules on cell surface were examined by flow cytometry analysis. Soluble ICAM-1 was detectable in IL-6 + sIL-6R-treated HUVEC and IL-6 + sIL-6R-induced ICAM-1 expression on cell membrane of HUVEC. In addition, U937 cells were added to HUVEC, which were pre-treated with IL-6 + sIL-6R for 24 h, and 3 h later attached U937 cells were counted. The adhesion of U937 cells to HUVEC was augmented when HUVEC was pretreated by IL-6 + sIL-6R. This adhesion was suppressed by anti-ICAM-1 antibody and anti-IL-6R antibody, but not by antibodies against VCAM-1 or E-selectin. In conclusion, IL-6 signaling plays an important role in inflammatory cell migration by increasing the rate of cell adhesion and by inducing chemokine production in inflamed joints.
Literatur
1.
Zurück zum Zitat Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M et al (2005) Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 5:1731–1740. doi:10.1016/j.intimp.2005.05.010 CrossRefPubMed Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M et al (2005) Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 5:1731–1740. doi:10.​1016/​j.​intimp.​2005.​05.​010 CrossRefPubMed
2.
Zurück zum Zitat Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T et al (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50:1761–1769. doi:10.1002/art.20303 CrossRefPubMed Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T et al (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50:1761–1769. doi:10.​1002/​art.​20303 CrossRefPubMed
3.
Zurück zum Zitat Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E et al (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987–997. doi:10.1016/S0140-6736(08)60453-5 CrossRefPubMed Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E et al (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987–997. doi:10.​1016/​S0140-6736(08)60453-5 CrossRefPubMed
4.
Zurück zum Zitat Uchiyama Y, Yorozu K, Hashizume M, Moriya Y, Mihara M (2008) Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis. Biol Pharm Bull 31:1159–1163. doi:10.1248/bpb.31.1159 CrossRefPubMed Uchiyama Y, Yorozu K, Hashizume M, Moriya Y, Mihara M (2008) Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis. Biol Pharm Bull 31:1159–1163. doi:10.​1248/​bpb.​31.​1159 CrossRefPubMed
6.
Zurück zum Zitat Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK et al (1992) Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 90:772–779. doi:10.1172/JCI115950 CrossRefPubMed Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK et al (1992) Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 90:772–779. doi:10.​1172/​JCI115950 CrossRefPubMed
7.
Zurück zum Zitat Seitz M, Dewald B, Gerber N, Baggiolini M (1991) Enhanced production of neutrophil-activating peptide-1/interleukin-8 in rheumatoid arthritis. J Clin Invest 87:463–469. doi:10.1172/JCI115018 CrossRefPubMed Seitz M, Dewald B, Gerber N, Baggiolini M (1991) Enhanced production of neutrophil-activating peptide-1/interleukin-8 in rheumatoid arthritis. J Clin Invest 87:463–469. doi:10.​1172/​JCI115018 CrossRefPubMed
9.
Zurück zum Zitat Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J (1988) Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 31:784–788. doi:10.1002/art.1780310614 CrossRefPubMed Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J (1988) Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 31:784–788. doi:10.​1002/​art.​1780310614 CrossRefPubMed
10.
Zurück zum Zitat Desgeorges A, Gabay C, Silacci P, Novick D, Roux-Lombard P, Grau G et al (1997) Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol 24:1510–1516PubMed Desgeorges A, Gabay C, Silacci P, Novick D, Roux-Lombard P, Grau G et al (1997) Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol 24:1510–1516PubMed
12.
13.
Zurück zum Zitat Leeuwenberg JF, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, Jeunhomme TM et al (1992) E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77:543–549PubMed Leeuwenberg JF, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, Jeunhomme TM et al (1992) E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77:543–549PubMed
14.
Zurück zum Zitat Hashimoto M, Shingu M, Ezaki I, Nobunaga M, Minamihara M, Kato K et al (1994) Production of soluble ICAM-1 from human endothelial cells induced by IL-1 beta and TNF-alpha. Inflammation 18:163–173. doi:10.1007/BF01534557 CrossRefPubMed Hashimoto M, Shingu M, Ezaki I, Nobunaga M, Minamihara M, Kato K et al (1994) Production of soluble ICAM-1 from human endothelial cells induced by IL-1 beta and TNF-alpha. Inflammation 18:163–173. doi:10.​1007/​BF01534557 CrossRefPubMed
15.
Zurück zum Zitat Pigott R, Dillon LP, Hemingway IH, Gearing AJ (1992) Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine-activated cultured endothelial cells. Biochem Biophys Res Commun 187:584–589. doi:10.1016/0006-291X(92)91234-H CrossRefPubMed Pigott R, Dillon LP, Hemingway IH, Gearing AJ (1992) Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine-activated cultured endothelial cells. Biochem Biophys Res Commun 187:584–589. doi:10.​1016/​0006-291X(92)91234-H CrossRefPubMed
16.
Zurück zum Zitat Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K et al (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48:1521–1529. doi:10.1002/art.11143 CrossRefPubMed Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K et al (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48:1521–1529. doi:10.​1002/​art.​11143 CrossRefPubMed
17.
Zurück zum Zitat Furie MB, McHugh DD (1989) Migration of neutrophils across endothelial monolayers is stimulated by treatment of the monolayers with interleukin-1 or tumor necrosis factor-alpha. J Immunol 143:3309–3317PubMed Furie MB, McHugh DD (1989) Migration of neutrophils across endothelial monolayers is stimulated by treatment of the monolayers with interleukin-1 or tumor necrosis factor-alpha. J Immunol 143:3309–3317PubMed
19.
Zurück zum Zitat Sung CP, Strorer B, Arleth A, Stadel J, Feuerstein G (1991) Evidence for the involvement of carbohydrate moieties in the adhesion of U937 cells to tumor necrosis factor-alpha (TNFalpha)-stimulated vascular endothelium in vitro. Agents Actions 34:205–207. doi:10.1007/BF01993280 CrossRefPubMed Sung CP, Strorer B, Arleth A, Stadel J, Feuerstein G (1991) Evidence for the involvement of carbohydrate moieties in the adhesion of U937 cells to tumor necrosis factor-alpha (TNFalpha)-stimulated vascular endothelium in vitro. Agents Actions 34:205–207. doi:10.​1007/​BF01993280 CrossRefPubMed
Metadaten
Titel
Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule
verfasst von
Miho Suzuki
Misato Hashizume
Hiroto Yoshida
Masahiko Mihara
Publikationsdatum
01.01.2010
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 3/2010
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-0953-0

Weitere Artikel der Ausgabe 3/2010

Rheumatology International 3/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.